THROMBOSIS AND HAEMOSTASIS

Scope & Guideline

Unlocking Insights in Thrombosis and Hemostasis

Introduction

Explore the comprehensive scope of THROMBOSIS AND HAEMOSTASIS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore THROMBOSIS AND HAEMOSTASIS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0340-6245
PublisherGEORG THIEME VERLAG KG
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 1976 to 2024
AbbreviationTHROMB HAEMOSTASIS / Thromb. Haemost.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRUDIGERSTR 14, D-70469 STUTTGART, GERMANY

Aims and Scopes

The journal 'Thrombosis and Haemostasis' focuses on advancing the understanding of thrombosis and hemostasis through the publication of high-quality research. It encompasses a wide range of topics related to blood coagulation, platelet function, vascular biology, and the management of thrombotic disorders.
  1. Thrombosis and Hemostasis Mechanisms:
    The journal emphasizes research on the underlying biological mechanisms of thrombosis and hemostasis, exploring the molecular, cellular, and genetic factors that contribute to these processes.
  2. Clinical Outcomes and Management Strategies:
    A significant focus is placed on clinical studies that assess the effectiveness of various anticoagulant therapies, management strategies for patients with thrombotic disorders, and the implications of these treatments on patient outcomes.
  3. Innovative Therapeutic Approaches:
    The journal highlights studies that explore novel therapeutic approaches for managing thrombotic and bleeding disorders, including the development of new anticoagulants and antiplatelet agents.
  4. Risk Assessment and Predictive Modeling:
    Research on risk factors and predictive models for thrombotic events is a key area of interest, aiming to improve risk stratification and patient management.
  5. Translational Research:
    The journal publishes findings that bridge basic science and clinical practice, facilitating the translation of laboratory discoveries into therapeutic applications for patients with thrombotic disorders.
The field of thrombosis and hemostasis is evolving, and recent publications in 'Thrombosis and Haemostasis' reveal several emerging trends and themes reflecting current research priorities and advancements in the field.
  1. COVID-19 and Thrombosis:
    A significant increase in research focusing on the relationship between COVID-19 and thrombotic events highlights the pandemic's impact on thrombosis research, emphasizing the need for understanding coagulopathy in infected patients.
  2. Personalized Medicine in Anticoagulation:
    Emerging studies emphasize the importance of personalized approaches to anticoagulation therapy, including tailoring treatments based on genetic, phenotypic, and clinical characteristics of patients.
  3. Machine Learning and Predictive Analytics:
    The integration of machine learning techniques for predicting thrombotic events and optimizing treatment strategies is gaining traction, reflecting a broader trend towards data-driven decision-making in healthcare.
  4. Cancer-Associated Thrombosis:
    Research specifically addressing the complexities of thrombosis in cancer patients is increasingly prevalent, focusing on the unique risk factors and management strategies required for this population.
  5. Innovative Biomarkers:
    There is a growing emphasis on identifying and validating novel biomarkers for predicting thrombosis and bleeding risks, which may enhance risk stratification and personalized treatment approaches.

Declining or Waning

While 'Thrombosis and Haemostasis' continues to publish a diverse array of topics, certain themes appear to be declining in prominence over recent years. This shift may reflect changes in research priorities or advancements in understanding that render previous topics less central to current discourse.
  1. Traditional Anticoagulant Therapies:
    There is a noticeable reduction in studies focused solely on traditional anticoagulant therapies such as warfarin, as newer agents like direct oral anticoagulants (DOACs) gain prominence in research.
  2. Basic Science of Hemostasis:
    Research that solely focuses on the basic science of hemostasis without practical clinical applications appears to be less frequent, as the journal shifts towards more clinically relevant studies.
  3. Static Risk Factor Studies:
    Studies that merely catalog risk factors without integrating them into predictive models or clinical applications are becoming less common, reflecting a trend towards more dynamic and actionable research.
  4. Single-Center Studies:
    There appears to be a decline in the publication of single-center studies as multi-center and larger cohort studies become the norm, likely due to the increased need for robust data in diverse populations.
  5. Pharmacokinetics of Established Drugs:
    Research focusing on the pharmacokinetics of well-established anticoagulants without new insights or comparative analyses is becoming less frequent, as emphasis shifts to novel agents and their clinical implications.

Similar Journals

Hamostaseologie

Transforming Hematological Knowledge: Essential Insights for Professionals
Publisher: GEORG THIEME VERLAG KGISSN: 0720-9355Frequency: 4 issues/year

Hamostaseologie is a prominent academic journal dedicated to the field of hematology, published by GEORG THIEME VERLAG KG. With an ISSN of 0720-9355 and an E-ISSN of 2567-5761, this journal has been at the forefront of critical research and advancements since its inception in 1981, and it continues to maintain its relevance in the scientific community with a converged publication until 2024. Ranked in the Q3 quartile in Hematology for 2023, and positioned at #44 out of 137 in the Scopus Medicine Hematology category, it represents a substantial contribution to scholarly discourse. Researchers and professionals alike will find valuable insights within its pages, as it disseminates rigorous studies and reviews that address pertinent issues related to hemostasis and coagulation. While the journal does not currently offer Open Access, readers can access its valuable content through institutional subscriptions, making it an essential resource for students, clinicians, and researchers aiming to deepen their understanding of hematological science.

AMERICAN JOURNAL OF HEMATOLOGY

Leading the Charge in Hematology Innovation
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Lancet Haematology

Leading the charge in hematological advancements.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

VASCULAR PHARMACOLOGY

Elevating the standards of vascular pharmacological research.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Advancing knowledge in thrombosis and thrombolysis.
Publisher: SPRINGERISSN: 0929-5305Frequency: 8 issues/year

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

Research and Practice in Thrombosis and Haemostasis

Bridging gaps in knowledge for hematology experts.
Publisher: ELSEVIERISSN: Frequency: 8 issues/year

Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.

Hematology-American Society of Hematology Education Program

Exploring Innovations in Hematological Science
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Journal of Atherosclerosis and Thrombosis

Advancing cardiovascular knowledge for a healthier future.
Publisher: JAPAN ATHEROSCLEROSIS SOCISSN: 1340-3478Frequency: 12 issues/year

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Unveiling Innovations in Hematology
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Iraqi Journal of Hematology

Connecting Global Scholars in Blood Science
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.